Operating in the dietary supplement industry with over 22 years of experience, Orzax announced its financial results for the first six months of 2026 on the Public Disclosure Platform (KAP). Following its initial public offering, the company sustained its operational momentum through domestic market penetration, production expansions, and strategic global investments.
Financial Highlights of the First Six Months of 2026
Key indicators from the financial disclosures include:
Revenue: Up 36% year-on-year to TL 4,525,914,424
Gross Profit: TL 2,963,470,934
EBITDA: TL 1,368,699,000
EBITDA Margin: 30%
Operating Profit: Increased by 24% year-on-year
Net Profit: Up 52% year-on-year to TL 306 million
Production Expansion and Global Investments
Supported by an extensive pharmacy distribution network reaching approximately 30,000 pharmacies across Turkey, Orzax is accelerating its international growth:
Capacity Expansion: Investments underway to increase production capacity by 36 million boxes.
Export Target: Aiming to lift the export share to 35% of total revenues within 5 years.
Kazakhstan Production Plant: Broke ground in July on a €35 million manufacturing facility, the company's largest overseas investment to date, supported by €25 million in EBRD financing.
India and Uzbekistan Entities: Established its direct subsidiary "ORZAX LIFE SCIENCES PRIVATE LIMITED" in Delhi, India, and completed subsidiary incorporation in Uzbekistan.
According to Grand View Research, the global dietary supplements market reached $209.5 billion in 2025 and is projected to expand at a compound annual growth rate (CAGR) of 9.5% between 2026 and 2033.
Statement from CEO Yunus Emre Alimoğlu
Yunus Emre Alimoğlu, CEO of Orzax, commented:
Our net profit of TL 306 million in the first half of 2026, alongside a 52% year-on-year net profit growth, reflects our sustainable growth roadmap and strong operating structure. We grew our revenues by 36% and operating profit by 24% on an annual basis. In line with our strategy, we are progressing toward a 25% compound annual growth rate for 2023–2027 and tripling our sales to reach TL 22 billion in revenue by 2029. While reinforcing our footprint in core markets including the US, the UK, Germany, Poland, and Kazakhstan, we are activating new growth drivers through R&D and innovation. By manufacturing localized probiotic raw materials and finished products from bacteria isolated in Turkey, we aim to reduce import dependency and secure a share in the $70+ billion global market.
